Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07064005 · ClinicalTrials.gov registry record · Phase 1
Enrichment of Glutathione Using Gamma-glutamylcysteine Supplementation in Parkinson's Disease Patients.
A Phase 1 study of Parkinsons Disease (PD), sponsored by Pravat Mandal.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 12
- Enrollment target
- 1
- Study location
NCT07064005: Recruiting Phase 1 study of Parkinsons Disease (PD), sponsored by Pravat Mandal.
NCT07064005 is a Phase 1 study of Parkinsons Disease (PD) that is actively recruiting participants, run by Pravat Mandal. The registered enrollment target is 12 participants, below the 119-participant average among 19 other Parkinsons Disease (PD) trials with a reported enrollment target (90% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07064005, a Phase 1 study of Parkinsons Disease (PD), is actively recruiting participants, sponsored by Pravat Mandal.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 12 participants
- Enrollment target
- 1
- Study location
Study Summary
This study is designed l to evaluate the effects of GGC oral supplementation in early Parkinson's disease (PD) patients. The main objectives of the study are to evaluate: 1. To study the enrichment of master antioxidant, glutathione (GSH) levels in brain and blood of these PD patients compared to baseline due to GGC supplementation. 2. To study the changes in motor function, cognitive skills in PD patients due to GGC oral supplementation 3. To study impact of GGC on gut health on the PD patients.
Primary Outcome
MEGA-PRESS is a non-invasive imaging technique, to detect various neurochemical (e.g., Glutathione) using 1H MR spectroscopy.
Conditions Studied
Interventions
- DRUG Gamma- glutamylcysteine
Study Locations (1)
Pennsylvania
- UPMC Presbyterian Hospital - Pittsburgh
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 12 participants |
| Start Date | 2026-03-20 |
| Est. Completion | 2027-11-27 |
| Phase | Phase 1 |
What NCT07064005 shows while recruiting
NCT07064005 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 12 participants, a relatively small participant target, below the 119-participant average among 19 other Parkinsons Disease (PD) trials with a reported enrollment target (90% lower).
The record links to 1 condition, with Parkinsons Disease (PD) appearing as the primary indexed condition, and to 1 intervention - of which Gamma- glutamylcysteine is the first listed.
NCT07064005 reports a single indexed study location in Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT07064005 about?
NCT07064005 is a clinical study titled "Enrichment of Glutathione Using Gamma-glutamylcysteine Supplementation in Parkinson's Disease Patients.". This study is designed l to evaluate the effects of GGC oral supplementation in early Parkinson's disease (PD) patients. The main objectives of the study are to evaluate: 1. To study the enrichment of master antioxidant, glutathione (GSH) levels in brain and blood of these PD patients compared to b...
What is the current status of trial NCT07064005?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 12 participants. The study started on 2026-03-20. Estimated completion is 2027-11-27.
What conditions does trial NCT07064005 study?
This clinical trial studies the following conditions: Parkinsons Disease (PD).
What interventions are being tested in trial NCT07064005?
The interventions under investigation include: Gamma- glutamylcysteine (DRUG).
Who is sponsoring clinical trial NCT07064005?
This trial is sponsored by Pravat Mandal, which has 3 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07064005 being conducted?
This trial has 1 study location across Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Parkinsons Disease (PD)
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT07064005's enrollment target sits among peer trials
12 20th of 19 the lowest of 19 other Parkinsons Disease (PD) trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Parkinsons Disease (PD) trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Subcutaneous Infusions of ABBV-951 in Subjects With Parkinson's Disease
COMPLETED · Phase 1
-
Evaluation of [18F]MNI-777 PET as a Marker of Tau Pathology in Subjects With Tauopathies Compared to Healthy Subjects
COMPLETED · Phase 1
-
A Study in Subjects With Parkinson's Disease to Evaluate the Safety and Tolerability of Titration and Continuous Subcutaneous Infusion of ABBV-951 in an Outpatient Environment
COMPLETED · Phase 1
-
Transcranial Direct Current Stimulation for Motor Function and Fatigue in PD
RECRUITING · NA
-
A Study of NE3107 in Early Parkinson's
RECRUITING · Phase 2
-
Study to Investigate Vagus Nerve Stimulation to Augment Executive Function in Healthy and Cognitively Impaired Populations
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02602769 · 12 participants
Whole Transcriptome Profiling and Metabolic Phenotyping in Children With ROHHAD Syndrome
- NCT02605421 · 12 participants · Phase 2
Myeloablative Consolidation Therapy and Tandem Autologous Stem Cell Rescue in Patients With High-Risk Neuroblastoma
- NCT02619448 · 12 participants · Early Phase 1
Concurrent Chemotherapy Plus HFR Radiation Therapy in Inoperable NSCLC
- NCT03311503 · 12 participants · Phase 1
Phase I/II Trial of Lentiviral Gene Transfer for SCID-X1 With Low Dose Targeted Busulfan Conditioning
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI